FindTrial
Sign In

Study of the use of drugs used for dyslipidemia by the patients of the Pharmaceutical Care Service of the 4th Regional of Irati-PR and evaluation of service satisfaction

Study of pharmacotherapeutic from the Clinical Protocol and Therapeutic Guidelines (PCDT / MS) of dyslipidemia applied to the Pharmaceutical Care Service of the 4th Regional of Irati-PR and evaluation of service satisfaction: A pharmacoepidemiological approach

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3yg34r
Enrollment
Unknown
Registered
2019-06-27
Start date
2017-07-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Interventions

The study was conducted from July 2017 to December 2017, totaling 06 months, in the Special Pharmacy of the 4th Regional Health of Irati-PR. INTERVENTION GROUP: 60 patients. Users older than 18 years
Second consultation, initial clinical intervention
Third consultation, situational analysis with detection of possible Related Problems (PRM) and its causes
Fourth consultation, planning of pharmaceutical care and interventions
Fifth consultation, analysis of results. CONTROL GROUP: 60 patients. Users older than 18 years, in use of 3 or more medications and with more than 3 comorbidities. 1 st. Meeting: protocol of first ph
Other
N02.421.668

Sponsors

Universidade Estadual de Maringá
Lead Sponsor
Universidade Estadual de Maringá
Collaborator

Eligibility

Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with dyslipidemia; using drugs from the Specialized Component of Pharmacy Assistance for dyslipidemia; over 18 years old; polymedicated; with more than 3 comorbidities.

Exclusion criteria

Exclusion criteria: Pregnant women; under 18; alcoholics; psychiatric disorder.

Design outcomes

Primary

MeasureTime frame
Reduction of the levels of total cholesterol, LDL and triglycerides and increase of the level of HDL cholesterol, in the period of six months, verified through the pharmacotherapeutic monitoring, from the study of the medicines used by the user and the analysis of the clinical and laboratory results collected.—

Secondary

MeasureTime frame
Reduction of hemoglobin A1C in diabetic patients and reduction of diastolic and systolic blood pressure, in the period of six months, verified through the pharmacotherapeutic monitoring, from the study of the medicines used by the user and the analysis of the clinical and laboratory results collected.;Reduction of hemoglobin A1C in diabetic patients and reduction of diastolic and systolic blood pressure, in the period of six months, verified through the pharmacotherapeutic monitoring, from the study of the medicines used by the user and the analysis of the clinical and laboratory results collected.—

Countries

Brazil

Contacts

Public ContactFernanda ;Fernanda Faria;Faria

Universidade Estadual de Maringá;Universidade Estadual de Maringá

ferlfaria@yahoo.com.br;ferlfaria@yahoo.com.br+55(42)999648141;42999648141

Outcome results

None listed

Source: REBEC (via WHO ICTRP)